| Identification | Back Directory | [Name]
ARS-1630 | [CAS]
1698055-86-5 | [Synonyms]
CPD2016
ARS-1630
ARS-1630;ARS 1630;ARS1630
inhibit,Ras,ARS-1630,ARS1630,Inhibitor,ARS 1630
(R)-1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one
2-Propen-1-one, 1-[4-[(7R)-6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)-4-quinazolinyl]-1-piperazinyl]- | [Molecular Formula]
C21H17ClF2N4O2 | [MOL File]
1698055-86-5.mol | [Molecular Weight]
430.84 |
| Chemical Properties | Back Directory | [Boiling point ]
614.7±55.0 °C(Predicted) | [density ]
1.434±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 69 mg/mL (160.15 mM) | [form ]
Solid | [pka]
6.03±0.35(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Uses]
ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1. | [Definition]
ChEBI: ARS-1620 is a qinazoline derivative carrying chloro and fluoro substituents at positions 6 and 8 respectively, a 2-fluoro-6-hydroxyphenyl group at position 7, and a 4-(prop-2-enoyl)piperazin-1-yl group at position 4. A potent, selective, and orally bioavailable covalent KRAS-G12C inhibitor, it inhibits the protein coding gene KRAS (Kirsten rat sarcoma virus) with high potency in cells and animals. It has a role as an inhibitor, an antiviral agent and an antineoplastic agent. | [IC 50]
KRAS(G12C) | [storage]
Store at -20°C | [References]
[1] Liansheng Li, et al. Inhibitors of kras g12c. WO 2015054572 A1.
[2] Janes MR, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018 Jan 25;172(3):578-589.e17. DOI:10.1016/j.cell.2018.01.006 |
|
|